These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38557898)

  • 1. The recent advancement of TCR-T cell therapies for cancer treatment.
    Zhao X; Shao S; Hu L
    Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(5):663-674. PubMed ID: 38557898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
    Chen L; Qiao D; Wang J; Tian G; Wang M
    Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
    Rath JA; Arber C
    Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating cancer with genetically engineered T cells.
    Park TS; Rosenberg SA; Morgan RA
    Trends Biotechnol; 2011 Nov; 29(11):550-7. PubMed ID: 21663987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting cancers through TCR-peptide/MHC interactions.
    He Q; Jiang X; Zhou X; Weng J
    J Hematol Oncol; 2019 Dec; 12(1):139. PubMed ID: 31852498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
    Sharma P; Kranz DM
    Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TCR-engineered T cells to treat tumors: Seeing but not touching?
    Debets R; Donnadieu E; Chouaib S; Coukos G
    Semin Immunol; 2016 Feb; 28(1):10-21. PubMed ID: 26997556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
    Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
    Front Immunol; 2021; 12():658753. PubMed ID: 33859650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redirected T cells in cancer therapy.
    Sangiolo D
    Expert Opin Biol Ther; 2015; 15(12):1667-70. PubMed ID: 26515608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Anticancer Potential of T Cell Receptor-Engineered T Cells.
    Ecsedi M; McAfee MS; Chapuis AG
    Trends Cancer; 2021 Jan; 7(1):48-56. PubMed ID: 32988787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
    Chandran SS; Klebanoff CA
    Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.
    Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D
    Curr Gene Ther; 2014 Feb; 14(1):52-62. PubMed ID: 24365144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [T cell receptor-based immunotherapy: a review].
    Chen Y; Gao GF; Tan S
    Sheng Wu Gong Cheng Xue Bao; 2023 Oct; 39(10):4004-4028. PubMed ID: 37877387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.
    Arnaud M; Bobisse S; Chiffelle J; Harari A
    Front Immunol; 2021; 12():701636. PubMed ID: 34394096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.
    Shafer P; Kelly LM; Hoyos V
    Front Immunol; 2022; 13():835762. PubMed ID: 35309357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication.
    Wolf SP; Anastasopoulou V; Drousch K; Diehl MI; Engels B; Yew PY; Kiyotani K; Nakamura Y; Schreiber K; Schreiber H; Leisegang M
    Clin Cancer Res; 2024 Apr; 30(8):1642-1654. PubMed ID: 38190111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive T-cell therapy for cancer: The era of engineered T cells.
    Bonini C; Mondino A
    Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput discovery of cancer-targeting TCRs.
    Bunse L; Green EW; Platten M
    Methods Enzymol; 2019; 629():401-417. PubMed ID: 31727251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.